No single treatment eliminates cough from pulmonary fibrosis, but several approaches can meaningfully reduce it. Low-dose morphine is the strongest performer in clinical trials so far, cutting daytime cough frequency by roughly 40% in one well-designed study. Beyond that, a combination of treating overlapping conditions like acid reflux, using specific breathing and cough-suppression techniques, avoiding known triggers, and in some cases trying off-label medications like thalidomide can bring the cough closer to manageable. The frustrating reality is that cough in pulmonary fibrosis has been undertreated for years, partly because the underlying disease itself drives the reflex in ways that standard cough medicines simply cannot address.
Why Pulmonary Fibrosis Makes You Cough So Much
Understanding the mechanism helps explain why over-the-counter cough syrups do almost nothing for this kind of cough. In pulmonary fibrosis, scar tissue gradually replaces healthy lung tissue, and the scarring tends to be worst at the base of the lungs. That structural distortion physically tugs on cough receptors embedded in the airways. Research has shown that low-frequency vibration applied over the lung base, where fibrosis is most extensive, triggers a cough response in more patients than stimulation at other sites, consistent with the idea that the warped architecture itself activates stretch-sensitive receptors in the lungs.1PubMed Central. Mechanical induction of cough in Idiopathic Pulmonary Fibrosis
On top of the mechanical distortion, the nerve endings in fibrotic lungs appear to be chemically rewired. Patients with idiopathic pulmonary fibrosis (IPF) have heightened sensitivity to capsaicin, the compound that makes chili peppers burn. Their sputum also contains higher levels of nerve growth factor and brain-derived neurotrophic factor, proteins that promote the survival and sensitization of sensory neurons.2PubMed. A study of the cough reflex in idiopathic pulmonary fibrosis These neurotrophins essentially turn up the volume on the cough reflex, making the lungs react to stimuli that healthy lungs would ignore.3European Respiratory Review. Cough in idiopathic pulmonary fibrosis – Section: Pathophysiology of cough in IPF The result is a cough that is both mechanically provoked and neurologically amplified, which is why it resists most conventional treatments.
How Cough Affects Daily Life
Cough is often the first symptom of pulmonary fibrosis, sometimes appearing before shortness of breath becomes noticeable. For most patients with IPF, chronic cough becomes a constant companion that goes well beyond a physical annoyance. It is linked to higher rates of depression and anxiety, worse physiological impairment, and faster disease progression.4PubMed Central. Cough in Idiopathic Pulmonary Fibrosis Research on progressive pulmonary fibrosis more broadly confirms that cough significantly erodes health-related quality of life, reinforcing the need for treatments that target the symptom directly rather than treating it as an afterthought.5Respiratory Medicine. Impact of cough burden on quality of life in progressive pulmonary fibrosis
One study that measured actual cough counts with recording devices found a strong relationship between how often patients coughed and how badly they rated the impact on their lives, but the cough frequency did not correlate well with standard lung function tests.6Cough. Objective cough frequency in Idiopathic Pulmonary Fibrosis That disconnect matters: your doctor might see stable numbers on a breathing test while you are coughing dozens of times an hour. If your cough is worsening your quality of life, it deserves attention even if your lung function measurements have not changed much.
Do Antifibrotic Drugs Help With Cough?
Pirfenidone and nintedanib are the two main medications approved to slow the progression of pulmonary fibrosis. Both target the scarring process itself, so a natural question is whether slowing fibrosis also quiets the cough. The evidence is mixed and somewhat contradictory.
A retrospective study of pirfenidone found that after six months of treatment, cough decreased in about 58% of patients.7PubMed. The Effectiveness, Safety, and Tolerability of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Retrospective Study That sounds encouraging, but a double-blind placebo-controlled trial in patients with unclassifiable progressive fibrosing lung disease showed no difference between pirfenidone and placebo on cough questionnaire scores at 24 weeks.8The Lancet Respiratory Medicine. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled phase 2 trial The discrepancy likely reflects the difference between observational data and a controlled trial: when you track patients on a drug without a comparison group, some improvement over time can happen for reasons unrelated to the medication.
Nintedanib paints a similarly ambiguous picture. A small preliminary study found no effect on cough or quality-of-life scores at one and three months.9European Respiratory Journal. Effect of nintedanib on cough and health related quality of life in patients with idiopathic pulmonary fibrosis However, a larger analysis of progressive pulmonary fibrosis patients over 52 weeks found that cough scores declined in the nintedanib group while worsening in the placebo group.10PubMed Central. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis The takeaway is that antifibrotic drugs might modestly help over longer periods, but they should not be relied upon as a primary cough treatment. If your cough is your main complaint, you need something more targeted.
Low-Dose Morphine
The most compelling evidence for directly treating pulmonary fibrosis cough comes from the PACIFY COUGH trial, a rigorous crossover study in which patients received both low-dose controlled-release morphine and a placebo at different times, with neither the patients nor the researchers knowing which was which. Morphine reduced objective daytime cough frequency by about 39% compared with placebo. In concrete terms, patients went from roughly 22 coughs per hour down to about 13 coughs per hour on morphine, while the placebo period produced essentially no change.11PubMed. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial
The doses used were low, and treatment adherence was very high at 98%, suggesting that side effects were tolerable for most people. Still, nausea and constipation were more common in the morphine group. About one in seven patients experienced nausea, and roughly one in five had constipation.12The Lancet Respiratory Medicine. Low-dose controlled-release morphine for cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a randomised, placebo-controlled, phase 2 trial These are manageable side effects for many people, especially when weighed against a cough that disrupts sleep, conversation, and emotional well-being. The trial lasted only 14 days per treatment arm, so longer-term data are still needed, but for now this is the strongest evidence-based option for reducing fibrotic cough.
One important caveat: this is not the kind of morphine use associated with addiction risk in pain management. The doses are very low and specifically targeted at the cough reflex. Still, prescribing opioids for a chronic condition requires careful discussion with a pulmonologist, and not every physician will be comfortable with it. Bringing up the PACIFY COUGH trial by name can help start that conversation.
Thalidomide and Gabapentin
Thalidomide has a notorious history, but in low doses it has shown real benefit for fibrosis-related cough. A randomized trial found that thalidomide significantly improved cough quality-of-life scores compared with placebo, along with improvements in respiratory symptoms and overall quality of life.13PubMed. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial Its anti-inflammatory and possible neuromodulatory effects may explain why it works where standard cough suppressants fail. The obvious concern is thalidomide’s well-known risk of birth defects and nerve damage, which means it is prescribed under strict safety programs, typically only when other options have failed, and never to anyone who could become pregnant.
Gabapentin, a drug originally developed for seizures but widely used for nerve pain, is another option that some pulmonologists try off-label. The rationale is that if the cough reflex in fibrosis is neurologically hypersensitized, a drug that dampens abnormal nerve signaling might help. A randomized, double-blind, placebo-controlled trial has been designed to formally test gabapentin at 900 mg per day for cough associated with interstitial lung disease, but results from that trial are not yet published.14PubMed Central. The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial In practice, many specialists already prescribe it based on evidence from chronic cough in general, where gabapentin has shown benefit. Drowsiness and dizziness are common side effects, especially when starting.
Experimental Treatments in the Pipeline
Several newer therapies are being investigated specifically for fibrosis-related cough. One of the more interesting is PA101, a reformulated version of sodium cromoglicate (a drug that has been used in asthma for decades) delivered through a high-efficiency nebulizer that deposits far more drug into the lungs than the older formulations. In a phase 2 trial, PA101 reduced daytime cough frequency by about 31% compared with placebo in patients with IPF over two weeks.15PubMed. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial That is a smaller effect than morphine achieved, but the drug appeared very well tolerated, and the researchers noted that the mechanism of cough in IPF may be distinct from chronic cough in general, which could guide future drug development.
Another avenue involves P2X3 receptor antagonists, a class of drugs that block a nerve receptor involved in the cough reflex. Gefapixant is the best-known drug in this class and has already been approved in some countries for refractory chronic cough. Computational research has explored its selective action on P2X3 receptors, which are implicated in diseases including IPF.16PubMed Central. P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough Whether P2X3 antagonists will work as well for fibrosis-driven cough specifically remains to be seen in dedicated trials. Not every drug that helps chronic cough in general translates well to fibrotic cough. A separate inhaled formulation called RVT-1601 tested in IPF patients failed to outperform placebo in a phase 2B study, a reminder that positive preliminary signals do not always hold up.17American Journal of Respiratory and Critical Care Medicine. Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
Speech Therapy and Cough-Suppression Techniques
Non-drug approaches are an underappreciated part of managing fibrotic cough. Speech therapists and physiotherapists can teach specific techniques that help you gain some voluntary control over the cough reflex. One structured program involved four sessions delivered by a physiotherapist and speech-language pathologist (conducted via video call, so accessibility is not a barrier). The sessions covered identifying personal cough triggers, breathing techniques for cough control, understanding the role of the larynx, and cough suppression strategies, with psychological support woven in through motivational interviewing.18Physiotherapy Canada. A Non-Pharmacological Cough Therapy for People with Interstitial Lung Diseases: A Case Report
Pulmonary rehabilitation programs also incorporate elements that can help. These typically include pursed-lip breathing, diaphragmatic breathing, thoracic expansion exercises, energy-saving techniques, and controlled coughing exercises.19PubMed Central. Effect of Home-Based Pulmonary Rehabilitation on Pulmonary Fibrosis Controlled coughing sounds counterintuitive, but the idea is to replace uncontrolled, exhausting coughing fits with a deliberate, less forceful technique that clears the airways without spiraling into prolonged spasms. Current expert reviews recognize that speech therapy and behavioral interventions offer a genuine complementary approach alongside medication.20PubMed Central. Cough and dyspnea management in pulmonary fibrosis
You do not need to wait for a referral to try some basics on your own. Sipping water at the first tickle of a cough urge, breathing slowly through your nose during a cough trigger, and humming or swallowing hard to interrupt the reflex are all strategies borrowed from speech therapy for chronic cough. They do not work every time, but patients report that even modest voluntary control over the reflex reduces the feeling of helplessness that makes the cough so psychologically draining.
Dealing With Acid Reflux
Acid reflux is extremely common in people with pulmonary fibrosis, and it has long been suspected of making the cough worse. The theory is that stomach acid creeping up the esophagus, and potentially being aspirated in tiny amounts into the lungs, irritates the airways and triggers coughing. Some data have even suggested that treating reflux with acid-suppressing drugs or surgery could slow fibrosis progression itself.21PubMed Central. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis Past international guidelines conditionally recommended proton pump inhibitors (PPIs) for IPF patients on this basis.22PubMed Central. Idiopathic pulmonary fibrosis and GERD: links and risks
The story has gotten more complicated. An intervention study that directly measured what happened to cough when IPF patients took acid-suppressing drugs found something surprising: although esophageal acid exposure dropped as expected, cough frequency did not improve. Even worse, non-acid reflux actually increased on the medication, raising concerns that PPIs might not be the simple fix they were once thought to be.23PubMed Central. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study More recent studies have also linked PPI use to a higher risk of lung infections, which is the last thing someone with compromised lungs needs.
This does not mean you should stop PPIs if you have genuine acid reflux with symptoms like heartburn or regurgitation. It means that taking acid-suppressing drugs purely to control the cough, without clear reflux symptoms, may not help and could carry its own risks. A thorough evaluation for reflux, including whether the reflux is acidic or non-acidic, is worth discussing with your care team. Specialist review of potential cough contributors like reflux and upper-airway issues is part of the recommended approach to managing cough in IPF.24PubMed. Managing Cough in Idiopathic Pulmonary Fibrosis
Identifying and Avoiding Your Personal Triggers
Beyond reflux, people with pulmonary fibrosis report a range of environmental and situational triggers that set off coughing. A qualitative study exploring how patients experience and self-manage their disease identified exercise, cold or dry air, powders, and low oxygen levels as common cough triggers.25BMJ Open Respiratory Research. Living with pulmonary fibrosis: how affected people experience disease-related information, health services and self-management strategies – Section: Cough These align with what the underlying science predicts: cold, dry air irritates hypersensitive nerve endings, exercise increases airflow velocity across scarred tissue, and low oxygen itself can activate cough pathways.
Practical steps that patients find helpful include:
- Humidifying indoor air: keeping humidity between 40% and 60% reduces the drying effect on airways, especially in winter or air-conditioned spaces.
- Wearing a scarf or mask: covering your nose and mouth in cold weather warms and moistens the air before it hits your lungs.
- Pacing physical activity: instead of pushing through exercise until the cough erupts, breaking activity into shorter intervals with rest periods can keep coughing below the threshold.
- Avoiding airborne irritants: dust, powders, strong fragrances, cleaning sprays, and smoke are common offenders. Switching to unscented household products and using a range hood when cooking can make a noticeable difference.
- Monitoring oxygen levels: if you use supplemental oxygen, ensuring adequate flow during activities that tend to desaturate you may help prevent cough triggered by low oxygen.
Trigger avoidance will not eliminate the cough, but reducing the frequency of avoidable flares can meaningfully improve your day-to-day comfort and reduce the total burden on already-irritated airways.
When the Cough Changes
A worsening cough in pulmonary fibrosis does not always mean the fibrosis itself is progressing. Infections, new medications, worsening reflux, or a completely unrelated cause like postnasal drip can all intensify coughing. This is why specialists recommend a systematic evaluation when the cough pattern shifts, looking at possible overlapping causes before attributing everything to the underlying fibrosis.24PubMed. Managing Cough in Idiopathic Pulmonary Fibrosis A new productive cough (bringing up colored sputum) in someone whose cough has always been dry, for instance, is a red flag for infection and warrants urgent medical attention.
Objective cough monitoring, where a small device records and counts actual coughs over 24 hours, is increasingly used in research and starting to appear in clinical practice.26European Respiratory Journal. Objective measurement of cough in pulmonary fibrosis: a cohort study – ImpaCT If your treatment center offers this kind of monitoring, it can give your medical team hard data on how well your current strategy is working, rather than relying on subjective impressions that are hard to compare visit to visit. Even without formal monitoring, keeping a simple log of your worst coughing times, your triggers, and any changes in pattern can help your doctor make better treatment decisions.